Covidien announced on 10 January that it had completed the previously announced acquisition of CV Ingenuity
CV Ingenuity’s core technology, which is still in the investigational phase, is a drug-coated balloon platform with a novel, proprietary, tunable, rapid-release system.
“We are pleased to add both the talented team members at CV Ingenuity as well as their promising drug-coated balloon technology to our growing portfolio of vascular products,” said Stacy Enxing Seng, president, Vascular Therapies, Covidien.“We are committed to being the clear first choice for our physician and hospital partners by delivering technology to improve patient outcomes.”
Covidien will report the CV Ingenuity business as part of its Vascular product line in the Medical Devices segment.
